Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLMIGI)

Drug Name
Belcesiran Drug Info
Indication
Disease Entry ICD 11 Status REF
Alpha-1 antitrypsin deficiency 5C5A Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMLMIGI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting SERPINA1 messenger RNA (SERPINA1 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fazirsiran DM772MW Alpha-1 antitrypsin deficiency 5C5A Phase 3 [3]
ARO-AAT DM2UP6Z Alopecia ED70 Phase 2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SERPINA1 messenger RNA (SERPINA1 mRNA) TT2L4TV A1AT_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04764448) A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Dicerna Pharmaceuticals
3 Fazirsiran for Liver Disease Associated with Alpha(1)-Antitrypsin Deficiency. N Engl J Med. 2022 Aug 11;387(6):514-524.
4 Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals.